Daval International Limited Gains Approval for Phase IIB Trial of AIMSPRO(R)

Daval International Limited Gains Approval for Phase IIB Trial of AIMSPRO(R)

November 26, 2007

    LONDON, Nov. 26 /Xinhua-PRNewswire/ -- Daval
International Limited, a UK private company, announces MHRA
and IRB (Ethics Committee) approval of a London based Phase
IIB trial of AIMSPRO(R), its hyperimmune caprine serum
derivative.

    This double-blind placebo-controlled cross-over study
will seek to detect a beneficial effect on bladder function
in patients with Secondary Progressive Multiple Sclerosis,
following open-label observations over several years in a
number of informed consent, "compassionate basis"
patients.

    AIMSPRO has an "export only" listing on the
Australian Registry of Therapeutic Goods and a TGA Orphan
Status Designation for the treatment of Krabbe's disease.
An IND application is being lodged for a further MS trial
in the United States.

    AIMSPRO is a frozen medication, given as a 1ml
sub-cutaneous injection every 4 days. It is believed to
have a pronounced and sustained anti-inflammatory action
with an associated, novel effect of lowering sodium channel
triggering voltages in nerve fibres. MHRA applications for
two further clinical trials are to be lodged within the
next 3 months.

    Daval International Ltd. has recently been accepted as
a member of the Association of the British Pharmaceutical
Industry. "ABE"

    Daval International Limited

    Daval International Limited is a privately owned
British pharmaceutical company, which, since 2001, has been
developing an immunologically active human and veterinary
medication derived from goat serum. Some 20.000 doses of
Aimspro have been administered, mainly to human subjects
with multiple sclerosis, with an excellent safety and
tolerance profile.



    For more information, please contact:

    Daval International Ltd
    Email: [e-mail]

     Dr. Bryan Youl
     Tel: [phone]

     Brian Quick
     Tel: [phone]